Healthcare Professionals

About HE4

Take the right treatment path.

The combination of the
CA125 + HE4 tests stratified
94% of all epithelial ovarian
cancers as high likelihood and
75% of all benign diseases
as low likelihood.

HE4 is a novel serum biomarker that, when combined with CA125, raises the level of sensitivity for the detection of ovarian cancer. It is an 11kDa protein that is a precursor to the epidiymal secretory protein E4 and is over expressed in ovarian carcinoma. Normal ovarian tissue has minimal gene expression and production of HE4.

Unlike CA125, HE4 is less frequently elevated in benign gynecological conditions, especially in premenopausal women21

BENIGN DISEASE
  PREMENOPAUSAL  
  POSTMENOPAUSAL  
HE4
CA125
HE4
CA125
Endometriosis/Endometrioma   
3%
72%
6%
18%
All Benign Tumors
6%
37%
12%
20%

In one study, HE4 and other tumor markers were evaluated in patients with ovarian cancer. Results showed that HE4 had the highest sensitivity as a single marker, and when HE4 and CA125 are combined the sensitivity is greater than either marker alone7

Read a summary of this study now

CA125 and HE4 were further evaluated using ROMA to determine the likelihood of malignancy in women presenting with a pelvic mass. The combination of the CA125+HE4 tests stratified 94% of all epithelial ovarian cancers as high risk and 75% of all benign disease as low risk.8

Read the summary of this study now

In addition, HE4 also is an accurate marker for monitoring of disease status in women with invasive epithelial ovarian cancer using serial testing. 75% of patient samples with no change in HE4 value correlated with no progression of disease and 78.7% of ovarian cancers evaluated were above the 150pM reference value.13

Videos